Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis ; volume:22 ; number:1 ; day:28 ; month:1 ; year:2022 ; pages:1-12 ; date:12.2022
BMC health services research ; 22, Heft 1 (28.1.2022), 1-12, 12.2022
- Urheber
-
Rezaee, Mehdi
Morowvat, Mohammad Hossein
Poursadeghfard, Maryam
Radgoudarzi, Armin
Keshavarz, Khosro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12913-022-07495-4
- URN
-
urn:nbn:de:101:1-2022050720404391398044
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rezaee, Mehdi
- Morowvat, Mohammad Hossein
- Poursadeghfard, Maryam
- Radgoudarzi, Armin
- Keshavarz, Khosro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab